Biocept Inc (BIOC) - Product Pipeline Analysis, 2018 Update

Biocept Inc (BIOC) - Product Pipeline Analysis, 2018 Update


  • Products Id :- GDME5968PD
  • |
  • Pages: 39
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. Biocept offers related instrumentation, OncoCEE technology, and analytical capabilities for rare event detection and genetic characterization. The company's OncoCEE platform modifies rare cell capture and analyses methods. It serves cancer diagnostic assays to oncologists and other physicians; hospitals, and cancer centers. Biocept also provides clinical trial and research services to pharmaceutical and biopharmaceutical companies; and clinical research organizations. Biocept is headquartered in San Diego, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Biocept Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Biocept Inc Company Overview 5

Biocept Inc Company Snapshot 5

Biocept Inc Pipeline Products and Ongoing Clinical Trials Overview 5

Biocept Inc - Pipeline Analysis Overview 7

Biocept Inc - Key Facts 7

Biocept Inc - Major Products and Services 8

Biocept Inc Pipeline Products by Development Stage 9

Biocept Inc Ongoing Clinical Trials by Trial Status 11

Biocept Inc Pipeline Products Overview 13

Companion Diagnostic Target Selector Test - SCLC 13

Companion Diagnostic Target Selector Test - SCLC Product Overview 13

MicroRNA Test - Lung Cancer 14

MicroRNA Test - Lung Cancer Product Overview 14

OncoCEE - CR (FISH) 15

OncoCEE - CR (FISH) Product Overview 15

preCEED 16

preCEED Product Overview 16

Target Selector CTC Test - EGFR Amplification 17

Target Selector CTC Test - EGFR Amplification Product Overview 17

Target Selector CTC Test - ESR1 18

Target Selector CTC Test - ESR1 Product Overview 18

Target Selector CTC Test - ESR1 Clinical Trial 19

Target Selector CTC Test - PTEN Deletion 20

Target Selector CTC Test - PTEN Deletion Product Overview 20

Target Selector ctDNA Test - ALK 21

Target Selector ctDNA Test - ALK Product Overview 21

Target Selector ctDNA Test - ALK Clinical Trial 22

Target Selector ctDNA Test - ESR1 23

Target Selector ctDNA Test - ESR1 Product Overview 23

Biocept Inc - Key Competitors 24

Biocept Inc - Key Employees 25

Biocept Inc - Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Biocept Inc, Recent Developments 27

Jul 17, 2018: Alliance Global to market Biocept liquid biopsy tests 27

Jun 18, 2018: Published Case Report Demonstrates the Clinical Utility of Biocept''''s CTC Platform in the Management of Patients with Metastatic Breast Cancer 27

Jun 11, 2018: VWR and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs 28

May 15, 2018: Biocept Announces First Quarter 2018 Financial Results 28

May 01, 2018: Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept''s Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer 30

Apr 27, 2018: Published Case Study Demonstrates the Clinical Utility of Biocept''s Liquid Biopsy Test for ALK Rearrangements 30

Mar 28, 2018: Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration 31

Mar 28, 2018: Biocept Reports 2017 Fourth Quarter and Full Year Financial Results 31

Mar 20, 2018: Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit 34

Mar 15, 2018: Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting 34

Appendix 36

Methodology 36

About GlobalData 39

Contact Us 39

Disclaimer 39

List of Figures

Biocept Inc Pipeline Products by Equipment Type 6

Biocept Inc Pipeline Products by Development Stage 9

Biocept Inc Ongoing Clinical Trials by Trial Status 11

List of Tables

Biocept Inc Pipeline Products and Ongoing Clinical Trials Overview 5

Biocept Inc Pipeline Products by Equipment Type 6

Biocept Inc Pipeline Products by Indication 6

Biocept Inc Ongoing Clinical Trials by Trial Status 6

Biocept Inc, Key Facts 7

Biocept Inc, Major Products and Services 8

Biocept Inc Number of Pipeline Products by Development Stage 9

Biocept Inc Pipeline Products Summary by Development Stage 10

Biocept Inc Ongoing Clinical Trials by Trial Status 11

Biocept Inc Ongoing Clinical Trials Summary 12

Companion Diagnostic Target Selector Test - SCLC - Product Status 13

Companion Diagnostic Target Selector Test - SCLC - Product Description 13

MicroRNA Test - Lung Cancer - Product Status 14

MicroRNA Test - Lung Cancer - Product Description 14

OncoCEE - CR (FISH) - Product Status 15

OncoCEE - CR (FISH) - Product Description 15

preCEED - Product Status 16

preCEED - Product Description 16

Target Selector CTC Test - EGFR Amplification - Product Status 17

Target Selector CTC Test - EGFR Amplification - Product Description 17

Target Selector CTC Test - ESR1 - Product Status 18

Target Selector CTC Test - ESR1 - Product Description 18

Target Selector CTC Test - ESR1 - Biocept's Liquid Biopsy Platform to Evaluate Cerebrospinal Fluid of Breast Cancer Patients for Metastatic Biomarkers 19

Target Selector CTC Test - PTEN Deletion - Product Status 20

Target Selector CTC Test - PTEN Deletion - Product Description 20

Target Selector ctDNA Test - ALK - Product Status 21

Target Selector ctDNA Test - ALK - Product Description 21

Target Selector ctDNA Test - ALK - Evaluation of Liquid Biopsies in Localized and Advanced Lung Cancer Patients 22

Target Selector ctDNA Test - ESR1 - Product Status 23

Target Selector ctDNA Test - ESR1 - Product Description 23

Biocept Inc, Key Employees 25

Glossary 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Affymax Inc

Celula Inc

AVIVA Biosciences Corp

Argos Therapeutics Inc

Biocept Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies

select a license
Single User License
USD 750 INR 53228
Site License
USD 1500 INR 106455
Corporate User License
USD 2250 INR 159683

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com